What Are The Five Key Differences Between A Good CDMO And A Great One?

By Karim Abdelkader, Chief Commercial Officer, INCOG BioPharma

The global biopharma industry and its CDMO partnerships collaborated to deliver more than 11.9 billion doses of COVID-19 vaccines across 184 countries worldwide in under a year, according to Bloomberg data. For much of the biotech and pharmaceutical industry, engaging expert external manufacturing partners, in a meaningful way with a unified objective, is essential for a successful drug development, technical product transfer and commercial launch strategy.

The injectable drug product contract manufacturing market is expected to grow exponentially over time—driven by an increasingly aging population, growing incidence of chronic diseases, innovative science and expanding bio/pharmaceutical drug development aimed at addressing such diseases. 

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage and quickly respond to clients’ short-term needs while anticipating and planning for their long-term requirements.

But with CDMO capacity available in certain capabilities, limited/constrained capacity elsewhere, and moreover inconsistent customer service—understanding what sets a good CDMO partner apart from a great CDMO partner is more relevant and important than ever to create exponential and long-term value.